Clinical Characteristics of Electrical Storm in Patients With Early Repolarization Syndrome.

Early repolarization syndrome J wave sudden death therapeutic hypothermia ventricular fibrillation

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
17 Jan 2024
Historique:
received: 20 10 2023
revised: 09 01 2024
accepted: 11 01 2024
medline: 20 1 2024
pubmed: 20 1 2024
entrez: 19 1 2024
Statut: aheadofprint

Résumé

Early repolarization syndrome (ERS) is an idiopathic ventricular fibrillation (VF) associated with inferolateral J waves. While electrical storms (ES) in ERS is not rare, their characteristics and risk factors are not fully understood. This study aimed to clarify the significance of ES in ERS. We evaluated 44 patients with ERS who experienced VF/sudden cardiac death or arrhythmic syncope. We assessed clinical characteristics to identify the risk factors for ES. In total, 13 patients (30%) experienced ES (ES group). Of these, 11 patients experienced ES during the acute phase of initial VF episodes, and 2 patients experienced ES during follow-up. VF associated with ES occurred during therapeutic hypothermia in 6 of 13 patients. The J wave voltage during therapeutic hypothermia was higher in the ES group than that in the non-ES group. Isoproterenol was used in 5 patients, which decreased J wave voltage and relieved ES. Among the clinical markers, shorter QT and QTp intervals (the interval from QRS onset to the peak of T wave), pilsicainide-induced ST-elevation, and high points on the Shanghai Score System (SSS) were associated with ES. Although pilsicainide induced ST elevation in 6 patients, spontaneous Brugada electrocardiographic patterns did not appear to be associated with VF. Therapeutic hypothermia was also a risk factor for acute-phase ES. Patients with ERS in the ES group frequently had short QT and QTp intervals, pilsicainide-induced ST elevations, and high SSS scores. Therapeutic hypothermia was also associated with acute phase ES.

Sections du résumé

BACKGROUND BACKGROUND
Early repolarization syndrome (ERS) is an idiopathic ventricular fibrillation (VF) associated with inferolateral J waves. While electrical storms (ES) in ERS is not rare, their characteristics and risk factors are not fully understood.
OBJECTIVE OBJECTIVE
This study aimed to clarify the significance of ES in ERS.
METHODS METHODS
We evaluated 44 patients with ERS who experienced VF/sudden cardiac death or arrhythmic syncope. We assessed clinical characteristics to identify the risk factors for ES.
RESULTS RESULTS
In total, 13 patients (30%) experienced ES (ES group). Of these, 11 patients experienced ES during the acute phase of initial VF episodes, and 2 patients experienced ES during follow-up. VF associated with ES occurred during therapeutic hypothermia in 6 of 13 patients. The J wave voltage during therapeutic hypothermia was higher in the ES group than that in the non-ES group. Isoproterenol was used in 5 patients, which decreased J wave voltage and relieved ES. Among the clinical markers, shorter QT and QTp intervals (the interval from QRS onset to the peak of T wave), pilsicainide-induced ST-elevation, and high points on the Shanghai Score System (SSS) were associated with ES. Although pilsicainide induced ST elevation in 6 patients, spontaneous Brugada electrocardiographic patterns did not appear to be associated with VF. Therapeutic hypothermia was also a risk factor for acute-phase ES.
CONCLUSIONS CONCLUSIONS
Patients with ERS in the ES group frequently had short QT and QTp intervals, pilsicainide-induced ST elevations, and high SSS scores. Therapeutic hypothermia was also associated with acute phase ES.

Identifiants

pubmed: 38242221
pii: S1547-5271(24)00027-4
doi: 10.1016/j.hrthm.2024.01.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Hiroshi Morita (H)

Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Electronic address: hmorita@cc.okayama-u.ac.jp.

Akira Ueoka (A)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Tomofumi Mizuno (T)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Takuro Masuda (T)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Saori Asada (S)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Kentaro Ejiri (K)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Masakazu Miyamoto (M)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Satoshi Kawada (S)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Koji Nakagawa (K)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Nobuhiro Nishii (N)

Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Shinsuke Yuasa (S)

Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.

Classifications MeSH